The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Multivalent veterinary vaccines. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
100+ innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 779,300 patents, there are 100+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, tyrosine kinase inhibitors, immunotherapy radiotherapy combination, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Chimeric flaviviruses, bacteriophage therapy, and microRNA are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are antibody encoding polynucleotide libraries and cell immunomodulation, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Multivalent veterinary vaccines are a key innovation area in pharmaceutical
The term multivalent/polyvalent veterinary vaccine is used to describe either a vaccine candidate with the ability to protect against several diseases or a vaccine candidate that can protect against several strains of a single pathogen used in domestic, livestock or wild animal. These vaccines are composed of active ingredients (antigens) and other adjuvants, inactivators, preservatives and excipients.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of multivalent veterinary vaccines.
Key players in multivalent veterinary vaccines – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to multivalent veterinary vaccines
Source: GlobalData Patent Analytics
C.H. Boehringer Sohn, the parent company of Boehringer Ingelheim group, is the leading patent filer in multivalent veterinary vaccines. The company is one of the largest providers of vaccines, parasiticides and therapeutics, complemented by diagnostics and monitoring platforms. BDA Blen, Marek's Disease Vaccine, Marek's SB1, and Recombitek C3 are some of the veterinary vaccines developed by the company.
In terms of application diversity, Assistance Publique - Hopitaux de Paris is the top company, followed by Angany and Virbac Group. By means of geographic reach, Sentinext Therapeutics holds the top position, while Mitsubishi Chemical Group and GSK are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.